Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)

Background: Relevant improvement in first-line treatment of metastatic pancreatic cancer (mPC) was provided by FOLFIRINOX and by gemcitabine (gem) plus nab-paclitaxel (Nab-p) regimens. Regardless of the first-line treatment survival benefit, most patients survive less than 1 year. Aim: The objective...

Full description

Bibliographic Details
Main Authors: Elisa Giommoni, Evaristo Maiello, Vanja Vaccaro, Ermanno Rondini, Caterina Vivaldi, Giampaolo Tortora, Laura Toppo, Guido Giordano, Tiziana Pia Latiano, Cinzia Lamperini, Serena Pillozzi, Luca Boni, Lorenzo Antonuzzo, Francesco Di Costanzo
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Current Oncology
Subjects:
metastatic pancreatic cancer
nab-paclitaxel
FOLFIRINOX
dose finding
Online Access:https://www.mdpi.com/1718-7729/28/3/164

Internet

https://www.mdpi.com/1718-7729/28/3/164

Similar Items